Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria (NHVs):
Inclusion Criteria (IPF Participants):
Exclusion Criteria (NHVs):
Exclusion Criteria (IPF Participants):
Note: additional inclusion/exclusion criteria may apply per protocol
Primary purpose
Allocation
Interventional model
Masking
97 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Medical Monitor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal